Doximity (DOCS) Resumen de Acciones
Doximity, Inc. opera como plataforma digital para profesionales de la medicina en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en DOCS a partir de nuestros controles de riesgos.
DOCS Community Fair Values
Create NarrativeSee what 84 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Doximity, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$25.77 |
| Máximo en las últimas 52 semanas | US$76.51 |
| Mínimo de 52 semanas | US$20.55 |
| Beta | 1.35 |
| Cambio en 1 mes | 13.18% |
| Variación en 3 meses | -26.89% |
| Cambio de 1 año | -54.87% |
| Variación en 3 años | -22.80% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -51.38% |
Noticias y actualizaciones recientes
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack
Apr 28
DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.Recent updates
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack
Apr 28DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.
DOCS: AI Tools And Share Buybacks Will Drive Shares Higher
Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook
The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher
Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
Feb 06
DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement
Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement
Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher
We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.DOCS: Budget Flush And Ad Shift Will Drive Shares Higher
Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Nov 14DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks
Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Sep 02We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve
Aug 15AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely
Jul 08With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case
Jun 23At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
May 17Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
May 01Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value
Apr 04What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You
Feb 23Doximity Q3 Earnings: Outpacing Even Management's Expectations
Feb 10When Should You Buy Doximity, Inc. (NYSE:DOCS)?
Jan 24Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Jan 13Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching
Jan 06Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Dec 06Doximity (NYSE:DOCS) Knows How To Allocate Capital
Dec 01Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%
Nov 13Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?
Nov 02Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 15Doximity: Downgrade To Hold On Valuation Concerns
Oct 03Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23
Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion
Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion.There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18Rentabilidad de los accionistas
| DOCS | US Healthcare Services | Mercado US | |
|---|---|---|---|
| 7D | 4.9% | 2.4% | 0.6% |
| 1Y | -54.9% | -37.2% | 28.4% |
Rentabilidad vs. Industria: Los resultados de DOCS fueron inferiores a los de la industria US Healthcare Services, que obtuvo un rendimiento del -37.2% el año pasado.
Rentabilidad vs. Mercado: DOCS obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.4% el año pasado.
Volatilidad de los precios
| DOCS volatility | |
|---|---|
| DOCS Average Weekly Movement | 7.7% |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: DOCS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DOCS (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2010 | 830 | Jeff Tangney | www.doximity.com |
Doximity, Inc. opera como plataforma digital para profesionales de la medicina en Estados Unidos. Su plataforma proporciona a sus miembros herramientas digitales creadas para la medicina, que les permiten colaborar con colegas, mantenerse al día de las últimas noticias e investigaciones médicas, gestionar sus carreras y horarios de guardia, agilizar la documentación y el papeleo administrativo y realizar visitas virtuales a pacientes. La empresa presta sus servicios principalmente a médicos, enfermeros, asistentes médicos, estudiantes de medicina, fabricantes farmacéuticos y sistemas sanitarios.
Resumen de fundamentos de Doximity, Inc.
| Estadísticas fundamentales de DOCS | |
|---|---|
| Capitalización bursátil | US$4.60b |
| Beneficios(TTM) | US$239.40m |
| Ingresos (TTM) | US$637.78m |
19.9x
Ratio precio-beneficio (PE)7.5x
Ratio precio-ventas (PS)¿Está DOCS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DOCS | |
|---|---|
| Ingresos | US$637.78m |
| Coste de los ingresos | US$65.39m |
| Beneficio bruto | US$572.39m |
| Otros gastos | US$333.00m |
| Beneficios | US$239.40m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
May 13, 2026
| Beneficios por acción (BPA) | 1.30 |
| Margen bruto | 89.75% |
| Margen de beneficio neto | 37.54% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado DOCS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/05 21:49 |
| Precio de las acciones al final del día | 2026/05/05 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Doximity, Inc. está cubierta por 32 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Nisala Weerasuriya | Berenberg |